Danaher Corporation (DHR) Earnings Call Transcripts

Danaher Corporation's Latest Earnings Call - Q2 FY2026

In the second quarter of 2026, Danaher Corporation (DHR:US) reported revenue of $6.3 billion, exceeding expectations, with core revenue growth of 3% year-over-year. Adjusted diluted EPS rose to $1.94, an 8% increase compared to the previous year. Management raised full-year adjusted EPS guidance to a range of $8.45 to $8.60, reflecting strong performance and the earlier-than-expected acquisition of Masimo, which is expected to be accretive to earnings.

Reported metrics

Guidance from management

Danaher raised its full-year adjusted diluted EPS guidance to a range of $8.45 to $8.60, reflecting a strong second quarter performance and the earlier-than-expected close of the Masimo acquisition. Management expects third-quarter revenue growth of approximately 2% to 3%.

What management said

So this is primarily related to resin shipments, Dan, that's about the one commonality that we can see here. And then look, building new plants and site readiness and so forth, just is not -- it's a complex business. It's -- it's not that scientific. So there are delays in that regard. But this is not related, let's say, on the back end to any one molecule that's out there in the market or just one customer, although...

Sure. First of all, Scott, thanks. We're really excited by the fact that we were able to get that acquisition closed a little bit earlier than we thought. And in our initial operating reviews, this is every fit the company that we thought it was. You might have heard there that we are already launched with a new 510(k) on a new assay. And so that's gone very well for us. And as we think about the growth rate, we vali...

What analysts pressed on

Analysts expressed concerns regarding the bioprocessing segment, particularly about shipment delays and the visibility of future revenue. Questions were raised about the potential impact of these delays on the overall growth outlook for the segment in the coming quarters.

Main topics on the call

• Revenue Growth Acceleration — Danaher experienced a core revenue growth acceleration to 4.5%, a 150 basis point increase from the first quarter. CEO Rainer Blair noted, "We were particularly pleased to see an acceleration in core growth versus the fi...
• Masimo Acquisition Impact — The acquisition of Masimo closed earlier than anticipated and is expected to contribute positively to earnings. Blair stated, "We expect Masimo to be immediately accretive both strategically and to adjusted EPS."
• Bioprocessing Revenue Timing Issues — Management highlighted delays in bioprocessing revenue due to shipment timing for large chromatography resin orders. CFO Matt Gugino mentioned, "We saw about a 500 basis points impact to that overall bioprocessing growth...
• Life Sciences Segment Growth — The Life Sciences segment reported a 5.5% increase in core revenue, driven by strong performance in filtration and automation. Blair commented, "We see good traction on our recent commercial and growth initiatives," indi...

Read the full Danaher Corporation transcript (Q2 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 61 Danaher Corporation earnings call transcripts on record, spanning January 14, 2020 to July 21, 2026. Based on this history, Danaher Corporation reports quarterly. The most recent call on file is dated July 21, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

DHR

Exchange

NYSE

Country

US

Sector

Health Care

Industry

Life Sciences Tools and Services

Calls on record

61

First call

January 14, 2020

Most recent

July 21, 2026

Reporting cadence

quarterly